Dr Ana Arance speaks to ecancer at ESMO 2019 in Barcelona about the IMspire170 trial for advanced melanoma.
She explains the study design and how the study did not reach the primary endpoint.
Dr Arance outlines some of the reasons why this could be the case, and what areas need to be looked at in more detail.